Download - LT from LV
![Page 1: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/1.jpg)
Solution by LT from LV
![Page 2: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/2.jpg)
Agenda
12/09/09 2
![Page 3: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/3.jpg)
Generic drugs producer Generic drugs & ingredients producer
Revenues by countries
![Page 4: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/4.jpg)
Generic drugs producerGeneric drugs &
ingredients producer
Product origin Product types
Intra-industryVertical (value chain)
Horizontal (competitors)Both Internal &Market Drivers
![Page 5: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/5.jpg)
Previous Sanitas Mergers
![Page 6: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/6.jpg)
Previous Sanitas Mergers
HB and Jelfa deals are identical
Capacity building/consolidation
Product and market extension
Geographic roll-up
Same cost and revenues synergies
All mergers operational
HB Slovak
Jelfa
Homeofarm
![Page 7: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/7.jpg)
Reactions
![Page 8: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/8.jpg)
Reactions
12/09/098
![Page 9: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/9.jpg)
Possible anti-trust case
Maximum market share in a country
Excessive bargaining power over distributorsNone, as drug stores chains are also very consolidated
The consolidated market share will not exceed 10% in any of the countries
Attention from Competition Council is highly unlikely
![Page 10: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/10.jpg)
Proposed Integration
![Page 11: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/11.jpg)
Organizational integration
![Page 12: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/12.jpg)
Revenues benefits
![Page 13: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/13.jpg)
Cost benefits
![Page 14: LT from LV](https://reader036.vdocuments.us/reader036/viewer/2022062300/559566c21a28ab3e478b4766/html5/thumbnails/14.jpg)
Questions are welcome!12/09/09 14